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Edited by Jesus AvilaAbstract We examined whether pathogenesis in dystrophin-
deﬁcient (mdx) mice and laminin-a2-deﬁcient (dy) mice is
ameliorated by bone marrow transplantation (BMT). Green
ﬂuorescent protein (GFP) mice were used as donors. In mdx
mice, BMT failed to produce any signiﬁcant diﬀerences in mus-
cle pathology, although some GFP-positive ﬁbers with restored
dystrophin expression were observed. In contrast, in the dy mice,
BMT led to a signiﬁcant increase in lifespan and an increase in
growth rate, muscle strength, and respiratory function. We con-
clude that BMT improved outcome in dy mice but not mdx mice.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The muscular dystrophies are groups of inherited myogenic
disorders characterized by progressive muscle wasting and
weakness of variable distribution and severity. Two major
types of severe muscular dystrophy, Duchenne muscular dys-
trophy (DMD) and congenital muscular dystrophy, have been
identiﬁed [1]. DMD is caused by mutations of the dystrophin
gene [2]. Most cases of congenital muscular dystrophy are
caused by mutations in the laminin-a2 chain (merosin) gene.
This disease has been termed merosin-deﬁcient congenital
muscular dystrophy (MCMD) or MDC1A [3]. Pathogenesis
of dystrophin-deﬁcient or laminin-a2-deﬁcient muscular dys-
trophy can be studied in mouse models [4]. Loss of dystrophin
protein is observed in the mdx mouse, the mouse model of
DMD [5]. The dystrophia muscularis (dy) mouse has spontane-
ous mutation in the Lama2 gene encoding laminin-a2 and is
used as a model of MDC1A [6,7]. Although some potential
treatments including pharmacologic methods, gene therapy,Abbreviations: BMT, bone marrow transplantation; DMD, Duchenne
muscular dystrophy; MDC1A, congenital muscular dystrophy type
1A; SpO2, arterial hemoglobin saturation
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doi:10.1016/j.febslet.2006.07.015and cell therapy have been tried, there are no eﬀective thera-
peutic approaches for muscular dystrophy at present [8].
Bone marrow transplantation (BMT) is an established clin-
ical procedure used to treat various human diseases. Adult
bone marrow (BM) cells contain mesenchymal stem cell pro-
genitors, which can give rise to osteocytes, chondrocytes, adi-
pocytes, and myocytes [9,10]. BM is also a promising source of
myogenic stem cells [11]. Recently, several investigators have
reported that transplanted BM cells participate in the muscle
regeneration process in irradiated recipient mice [12–15] or
DMD patient [16]. However, analyses of these studies are often
limited to histopathologic assessments.
In the present study, we examined the therapeutic eﬀect of
whole BMT on muscular dystrophy model mice by evaluating
clinical phenotypes such as body weight, lifespan, muscle
strength, and respiratory function as well as histopathology.
We also compared the therapeutic eﬀect of whole BMT on
two distinct models of muscular dystrophy, mdx and dy mice.
Our results showed that BMT improved outcome in dy mice
but failed to aﬀect pathology of mdx mice. Thus a therapeutic
approach of transplanting BM cells could be considerable
beneﬁt in MDC1A.2. Materials and methods
2.1. Mice
The C57BL/6 (wild-type) mice were purchased from Clea Japan
(Tokyo, Japan). The mdx mice (of C57BL/10 background) were pro-
vided by Central Institute for Experimental Animals (Kanagawa,
Japan). The laminin-a2-deﬁcient Lama2/ mice (dy) mice and the
EGFP transgenic (GFP-Tg) mice with a C57BL/6 background [17]
were purchased from Jackson Laboratory (Bar Harbor, Maine,
USA). All experiments involving animals were performed under the
guidelines of the Institutional Animal Care and Research Advisory
Committee, Kawasaki Medical School.
2.2. Bone marrow reconstitution
BM chimeras were established by following the method of Fukada
et al. [15] with modiﬁcations. Brieﬂy, adult (8-week-old) wild-type,
mdx or dy mice received 9 Gy TBI (X-ray), split into two doses sepa-
rated by 3 h to minimize gastrointestinal toxicity. BMT was performed
according to a standard protocol described previously [18,19]. Recipi-
ent mice were injected with 5 · 106 T cell-depleted BM cells. T cell
depletion of donor BM cells was performed using anti-CD90-Micro-
Beads and an AutoMACS system (Miltenyi Biotec, Auburn, CA,
USA) according to the manufacturer’s instructions. No unfavorable
results such as GVHD were observed in recipient mice received BM
cells from GFP mice.blished by Elsevier B.V. All rights reserved.
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Fig. 1. Kaplan–Meier survival curves for BMT or non-treated control
groups of each model of mice (n = 10, each). Arrow indicates 8 weeks
of age at the time of BMT was performed. BMT (), control group;
BMT (+), treated group.
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Cryosections of diaphragm muscle were prepared as described previ-
ously [20]. For immunohistochemical analysis, sections were immuno-
stained with a rabbit polyclonal antibody against GFP (MBL, Nagoya,
Japan) or a monoclonal antibody against C-terminus of dystrophin
(NCL-DYS2; Novocastra, Newcastle, United Kingdom), laminin-a2
(merosin) (clone 4H8-2; Sigma–Aldrich, St. Louis, MO, USA) fol-
lowed by ﬂuorescein isothiocyanate-conjugated secondary antibodies
according to the MOM procedure (Vector Laboratories, Burlingame,
CA, USA). The slides were mounted with VECTASHIELD plus DAPI
(Vector Laboratories). The ﬂuorescence images were recorded photo-
graphically using a microscope (Nikon, Tokyo, Japan) and analyzed
with Lumina Vision software (Mitani Corporation, Fukui, Japan).
2.4. Grip strength test and pulse oximetry
Peak grip strength (g) was measured using an MK-380S automated
grip strength meter (Muromachi Kikai, Tokyo, Japan) as described
previously [21]. Arterial hemoglobin saturation (SpO2) was measured
with Masimo SET (Masimo Corp., Irvine, CA, USA) [22].
2.5. Statistics
Statistical analysis was performed on paired observations using Bon-
feroni’s test after one-way ANOVA.3. Results
3.1. BMT promotes survival and growth of laminin-a2-
deﬁcient mice
We ﬁrst examined whether BMT aﬀects lifespan in the mdx
mice and dy mice. Kaplan–Meier survival curves revealed that
a large percentage of control dy mice died around the ﬁrst 20
weeks after birth (Fig. 1), whereas dy mice that received
BMT survived up to 40 weeks, or almost double the lifespan
of control dy mice. In mdx mice, we kept both groups of mice
up to 2 years and found no diﬀerence for lifespan betweenB
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Fig. 2. (A) Growth curves for mdx mice between the control and BMT gro
Growth curves for dy mice until 12 weeks after BMT (n = 5, each). Data ar
ANOVA. BMT (), control group; BMT (+), treated group.BMT and control groups. These results indicate that BMT
eliminated early death of dy mice.
We further examined progressive changes in body weight of
these models. BMT did not aﬀect the growth rate of mdx mice
in both males and females (Fig. 2A). The dy mice that received
BMT lost weight right after BMT but gained weight more
quickly and grew signiﬁcantly larger than non-treated litter-
mates (Fig. 2B). This tendency was found in both males and
females. Thus, in addition to increasing lifespan, BMT im-
proved the growth of dy mice.
3.2. BMT dose not signiﬁcantly alter pathology in mdx muscle
We then questioned weather BMT improves muscle pathol-
ogy of mdx mice. We examined diaphragm muscle, known tos after BMT)
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ups in males or females up to 16 weeks after BMT (n = 5, each). (B)
e expressed as means ± S.D. *P < 0.05, Bonferoni’s test after one-way
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staining of diaphragm muscles both in BMT and control
groups showed characteristic of dystrophic change including
ﬁber size variability, central nucleus, ﬁbrosis and fatty replace-
ment. There is no detectable diﬀerence in gross pathology
between both groups (data not shown). Next, diaphragm mus-
cle sections of wild-type, control, and BMT group were stained
for GFP and dystrophin immunoreactivity and DAPI (Fig. 3).
We successfully obtained GFP-positive muscle ﬁber generation
in irradiated BM chimeras. The frequency of GFP-positive ﬁ-
bers in diaphragm muscle was 4.9 ± 2.2% of total muscle ﬁbers
(n = 3). The frequency of dystrophin-positive ﬁbers in dia-
phragm muscle was 0.9 ± 0.1% (n = 3). Merge images of mdx
mice that underwent BMT revealed few GFP-positive ﬁbers
with dystrophin expression restored. Although some GFP-po-
sitive BM-derived skeletal muscles were observed, dystrophin
expression was limited in mdx mice. These results indicate that
muscle pathology was not signiﬁcantly improved by BMT in
mdx mice.
3.3. BMT improves pathology and signiﬁcantly restores laminin-
a2 expression in dy muscle
We next examined muscle pathology of dy mice. H&E stain-
ing of diaphragm muscles of dy mice in control group showed
degenerative changes and atrophy in comparison with wild-
type mice. Although degenerative changes are still observed,
thickness of diaphragm muscles of dy mice is restored close
to that of wild-type mice after BMT (Fig. 4A). We immuno-Fig. 3. Immunohistochemistry of diaphragm muscle sections of wild-type (W
group (mdx-BMT, right column). Merge image of mdx-BMT revealed that som
heads). Bottom row is higher magniﬁcation of merge image. Bars: 100 lm. Bstained muscle sections of wild-type and dy mice (both control
and BMT groups) with GFP and laminin-a2 antibodies and
DAPI (Fig. 4B). The frequency of GFP-positive ﬁbers in dia-
phragm muscle was 61.7 ± 5.9% of total muscle ﬁbers
(n = 3). The frequency of laminin-a2-positive ﬁbers in dia-
phragm muscle was 82.6 ± 3.9% (n = 3). The merge image
showed a signiﬁcant number of GFP-positive ﬁbers with lam-
inin-a2 expression. Of particular importance, laminin-a2
expression was restored not only in GFP-positive ﬁbers but
also in GFP-negative ﬁbers. In contrast to mdx mice, BM cells
engrafted into skeletal muscle of dy mice with robust GFP-
positive cells and laminin-a2 expression was signiﬁcantly
restored.
3.4. BMT improved muscle strength in dy mice
We measured the peak force of grip strength of mice. The
grip strength of the dy mice that underwent BMT was signiﬁ-
cantly stronger (P < 0.05) than the dy control mice at 12 weeks
after BMT (Fig. 5B). On the other hand, there were no sub-
stantial diﬀerences between the two groups of mdx mice
(Fig. 5A). The ratio of grip strength per body weight revealed
that BM transplanted dy mice had restored the ratio close to
that of wild-type and mdx mice (Fig. 5C).
3.5. BMT improved respiratory function of dy mice
The SpO2 measurements of mdx mice revealed no signiﬁcant
diﬀerences between control and BMT groups (Fig. 6A). In
contrast, dy mice underwent BMT retained higher oxygenT-control, left column), control (mdx-control, middle column) or BMT
e GFP-positive ﬁbers with dystrophin expression were restored (arrow
MT (), control group; BMT (+), treated group.
Fig. 4. BMT improved histopathology of dy muscles. (A) H&E staining of diaphragm muscle sections of wild-type (WT-control, left column),
control (dy-control, middle column), or BMT group (dy-BMT, right column). (B) Immunohistochemistry of diaphragm muscle sections of wild-type
(WT-control, left column), control (dy-control, middle column), or BMT group (dy-BMT, right column). Note that merge image of dy-BMT revealed
a signiﬁcant number of GFP-positive ﬁbers with laminin-a2 expression. Of particular importance, laminin-a2 expression was restored not only in
GFP-positive ﬁbers but also in GFP-negative ﬁbers (arrow heads). Bottom row is higher magniﬁcation of merge image. Bars: 100 lm. BMT (),
control group; BMT (+), treated group.
4466 H. Hagiwara et al. / FEBS Letters 580 (2006) 4463–4468saturation and control dy mice showed decreased hypoxia at
20 weeks of age (12 weeks after BMT) (Fig. 6B).4. Discussion
We found that BMT led to no signiﬁcant improvements in
muscle pathology of mdxmice. This result is consistent with re-
cent reports [12–15]. We also found there was some discrep-
ancy between GFP and dystrophin expressions in mdx mice
that received BMT. This discrepancy is similar to that of a re-
cent report describing that up to 5% of total muscle ﬁbers ex-
pressed GFP, whereas dystrophin restoration after BMT was
always <1% of total muscle ﬁbers [24]. We also demonstrated
that BMT failed to aﬀect lifespan, growth rate, grip strength,
and respiratory function of mdx mice. Taken together, BMT
is unlikely to signiﬁcantly ameliorate pathogenesis in dystro-
phin-deﬁcient muscle.In contrast to mdx mice, BMT led to a signiﬁcant increase in
lifespan and an increased growth rate of dy mice. Diaphragm
muscle pathology of dy mice was also improved by BMT. Of
particular signiﬁcance is that laminin-a2, which is deﬁcient in
dy mice, was restored not only in GFP-positive myoﬁbers
but also GFP-negative myoﬁbers. Additionally, BMT im-
proved muscle strength and respiratory function of dy mice.
This is the ﬁrst report to demonstrate that BMT improves clin-
ical symptoms of a mouse model of muscular dystrophy. Our
study indicates that muscular dystrophy due to loss of laminin-
a2 can be signiﬁcantly ameliorated by BMT. Thus BMT could
be an eﬀective therapy for laminin-a2-deﬁcient muscular dys-
trophy.
The reason why BMT was eﬀective in dy mice but not mdx
mice remains to be clariﬁed. Two possible mechanisms to
correct dystrophic pathology in dy mice by BMT are consid-
ered. First, the circulating BM-derived cells more easily fuse
into host dystrophic cells through disrupted basal lamina in
Age (weeks after BMT) 
0 4 8 12 16
G
rip
 s
tre
ng
th
 (g
ra
m)
250
200
150
100
0
50
*
Age (weeks after BMT) 
0 4 8 12
G
rip
 s
tre
ng
th
 (g
ra
m)
250
200
150
100
0
50
mdx BMT (+)mdx BMT ( ) dy BMT ( ) dy BMT (+)
WT BMT ( ) WT BMT (+)
A B
C
G
rip
 s
tre
ng
th
 / 
BW
dy
BMT
( )
dy
BMT
(+)
mdx
BMT
( )
mdx
BMT
(+)
10
8
6
4
2
0
*
Fig. 5. Peak force measurement (g) of grip strength. (A)mdxmice before, 4, 8, 12, and 16 weeks after BMT (n = 7, each). (B) dymice before, 4, 8, and
12 weeks after BMT (n = 7, each). Note that the grip strength of dy-BMT mice was signiﬁcantly stronger than dy-control mice at 12 weeks after BMT.
(C) Representation of grip strength per body weight of each group. Data are expressed as means ± S.D. *P < 0.05, Bonferoni’s test after one-way
ANOVA. BMT (), control group; BMT (+), treated group.
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by BM-derived cells diﬀuse in the vicinity to form normal
laminin-2 networks even in GFP-negative myoﬁbers. In con-
trast, in mdx mice, the basal lamina is so well-preserved that
foreign BM-derived cells could not integrate into recipient
cells.
In addition to MDC1A, BMT could be eﬀective for other
types of dystrophy including Fukuyama congenital muscular
dystrophy, muscle-eye-brain disease, and Walker–Warburg
syndrome in which partial laminin-a2 deﬁciency and disrup-
tion of basal lamina are commonly observed [25].
In conclusion, on the basis of our results, BMT may be more
successful in the treatment of muscle diseases such as MDC1A
than DMD.Fig. 6. SpO2 measurements. (A) mdx mice before and 12 and 32
weeks after BMT (n = 5, each). (B) dy mice before BMT and 12
weeks after BMT. Note that SpO2 of dy-BMT group retained higher
oxygen saturation whereas the dy-control group showed a decrease in
hypoxia (n = 5, each). Arrow indicates 8 weeks of age at the time of
BMT was performed. BMT (), control group; BMT (+), treated
group.
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